ASCO® 2024 Highlights: Presenter Vignette – Tom John

Dr. Tom John

Tom John

PhD, FRACP, MBBS

Peter MacCallum Cancer Centre

Abstract# 8005

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).